
Minerva Neurosciences (NERV) Stock Forecast & Price Target
Minerva Neurosciences (NERV) Analyst Ratings
Bulls say
Minerva Neurosciences is well-positioned to potentially disrupt the current market for schizophrenia treatment with its promising drug, roluperidone, which addresses the unmet need for a treatment for negative symptoms. With strong patent protection and positive clinical trial results, the company has the potential to become a major player in the biopharmaceutical industry. Investors should keep a close eye on the ongoing Phase 3 trial and the FDA's response to the potential approval of roluperidone.
Bears say
Minerva Neurosciences is expected to experience negative financial and legal impacts due to the unimpressive results of its confirmatory Phase 3 study for the drug Roluperidone, which has the potential to be the first approved therapy for negative symptoms in schizophrenia patients. The company's recent financing activities demonstrate its need for additional capital, possibly indicating a lack of confidence in the drug's future success. However, its post-hoc analysis showed promising results for both doses, supported by highly significant responder rates, which could lead to a potential approval in the future.
This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.
Minerva Neurosciences (NERV) Analyst Forecast & Price Prediction
Start investing in Minerva Neurosciences (NERV)
Order type
Buy in
Order amount
Est. shares
0 shares